Followers | 25 |
Posts | 1513 |
Boards Moderated | 0 |
Alias Born | 12/14/2006 |
Sunday, May 08, 2011 11:27:54 PM
Teva has outbid Valeant in its offer to buy Cephalon, citing interest in Mesoblast's stem cell therapies.
Mesoblast's mesenchymal stem cells under the microscope.
It's an acquisition frenzy as Teva Pharmaceutical Industries has made a US$6.2 billion bid for Cephalon in the wake of the latter's partnership with Australian regenerative medicine company Mesoblast.
The takeover bid trumps a similar bid made by Valeant Pharmaceuticals International, offering a 12 per cent premium on the Valeant's offering. Valeant has subsequently withdrawn its offer.
The Israel-based Teva is offering US$81.50 a share for Cephalon, valuing the company at US$6.8 billion.
Teva cited Cephalon's recent deal with Mesoblast as being one of the elements that inspired the takeover, considering the high-risk but high-reward technology to be very desirable.
Currently Teva's big breadwinner is its multiple sclerosis treatment Copaxone, which comes off patent in 2012. As such, it's on the hunt for the next generation of drugs and biologics, and considers Cephalon-Mesoblast to be a rich source of potential money earners in these areas.
Melbourne-based ChemGenex, which is working to bring its anti-chronic myeloid leukaemia drug, Omapro, to the market, has also been caught up in the takeover shenanigans.
Cephalon was mid-acquisition of ChemGenex when the Valeant and now Teva bids manifest, although ChemGenex insists that the takeover of Cephalon will not disrupt its own deal, which is progressing as planned.
Mesoblast (ASX:MSB) shares lifted another 6.2% in yesterday's trading, to $9.26, and is up nearly 19% over the past 30 days.
ChemGenex is steady at 69c, rising nearly 8% over the month.
http://www.lifescientist.com.au/article/385422/mesoblast_deal_inspires_teva_swoop_cephalon/
________________________
MBLTY is on fire but is competitor PSTI really 25x behind in valuation?
Everything I state is just my own opinion so do your own DD.
Buying great stocks is important but buying great stocks at a great price is even more important.
Recent MESO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:14:45 AM
- Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 • GlobeNewswire Inc. • 08/28/2024 11:27:43 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 08/27/2024 11:25:57 PM
- Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 07/31/2024 01:13:29 AM
- FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/23/2024 11:53:49 AM
- Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain • GlobeNewswire Inc. • 07/22/2024 12:45:12 AM
- Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/09/2024 12:37:09 AM
- Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week • GlobeNewswire Inc. • 07/01/2024 05:55:36 AM
- Mesoblast Corporate Presentation at Investor Conference • GlobeNewswire Inc. • 06/03/2024 12:23:37 AM
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 • GlobeNewswire Inc. • 04/30/2024 01:05:17 AM
- FDA Commentary Sends Biotech Soaring During Premarket Hours • AllPennyStocks.com • 03/26/2024 01:25:00 PM
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 03/26/2024 02:34:20 AM
- Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer • GlobeNewswire Inc. • 03/13/2024 11:30:47 PM
- United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) • GlobeNewswire Inc. • 03/10/2024 11:54:12 PM
- Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/28/2024 10:57:09 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 02/15/2024 12:46:40 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 • GlobeNewswire Inc. • 01/31/2024 02:13:34 AM
- Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment • Dow Jones News • 01/19/2024 12:28:00 AM
- United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 01/18/2024 11:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:33:54 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/05/2024 02:57:09 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 12/22/2023 10:13:02 PM
- Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease • GlobeNewswire Inc. • 11/26/2023 11:56:21 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM